文献速递临床试验与 GCP真实世界研究与卫生经济

抗生素或银涂层脑室腹腔分流管与标准分流管比较(BASICS):多中心、单盲、随机试验及经济评价

Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation.
PubMed 文献 · Lancet · 2019-09-12

BASICS试验在英国和爱尔兰21个神经外科中心纳入1605例首次行脑室腹腔分流术的脑积水患者,随机分为标准分流管组、抗生素浸渍分流管组和银浸渍分流管组。结果显示抗生素分流管组感染翻修率显著低于标准分流管组(2% vs 6%,csHR 0.38),银分流管组与标准组无显著差异。作者认为证据支持英国首次分流患者采用抗生素分流管。

要点

  • 抗生素分流管组感染翻修率为2%,显著低于标准分流管组的6%(csHR 0.38)。
  • 银分流管组感染翻修率为6%,与标准分流管组无显著差异(csHR 0.99)。
  • 三组不良事件均非危及生命,主要与阀门或导管功能相关。

核心结论

  • BASICS试验提供证据支持英国首次行脑室腹腔分流术的患者采用抗生素分流管。
  • 该做法通过降低分流感染的风险和危害使所有年龄的患者获益。

研究设计与样本

  • 平行、多中心、单盲、随机对照试验,在英国和爱尔兰21个成人及儿科神经外科中心进行。
  • 纳入任何病因的脑积水、接受首次脑室腹腔分流术的患者,不限年龄。
  • 2013年6月26日至2017年10月9日评估3505例患者,1605例随机分配至标准分流管组(n=536)、抗生素分流管组(n=538)或银分流管组(n=531)。
  • 随机分配比例为1:1:1,采用区组大小为3或6的随机置换区组,随机序列由独立统计师生成。
  • 1594例在置入时无感染证据者置入分流管(标准组533例、抗生素组535例、银组526例),中位随访22个月(IQR 10-24),53例退出随访。

主要发现

  • 标准分流管组533例可评估患者中32例(6%)因感染行分流管翻修。
  • 抗生素分流管组535例可评估患者中12例(2%)因感染行分流管翻修,与标准组相比csHR 0.38(97.5% CI 0.18-0.80,p=0.0038)。
  • 银分流管组526例患者中31例(6%)因感染行分流管翻修,与标准组相比csHR 0.99(97.5% CI 0.56-1.74,p=0.96)。
  • 标准分流管组135例(25%)、抗生素分流管组127例(23%)、银分流管组134例(36%)发生不良事件,均非危及生命,主要与阀门或导管功能相关。

临床怎么用

  • 作者认为证据支持英国首次行脑室腹腔分流术的患者采用抗生素分流管。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest neurosurgical procedures worldwide. Infection of the implanted shunt affects up to 15% of these patients, resulting in prolonged hospital treatment, multiple surgeries, and reduced cognition and quality of life. Our aim was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shunts at reducing infection. METHODS: In this parallel, multicentre, single-blind, randomised controlled trial, we included patients with hydrocephalus of any aetiology undergoing insertion of their first ventriculoperitoneal shunt irrespective of age at 21 regional adult and paediatric neurosurgery centres in the UK and Ireland. Patients were randomly assigned (1:1:1 in random permuted blocks of three or six) to receive standard shunts (standard shunt group), antibiotic-impregnated (0·15% clindamycin and 0·054% rifampicin; antibiotic shunt group), or silver-impregnated shunts (silver shunt group) through a randomisation sequence generated by an independent statistician. All patients and investigators who recorded and analysed the data were masked for group assignment, which was only disclosed to the neurosurgical staff at the time of operation. Participants receiving a shunt without evidence of infection at the time of insertion were followed up for at least 6 months and a maximum of 2 years. The primary outcome was time to shunt failure due the infection and was analysed with Fine and Gray survival regression models for competing risk by intention to treat. This trial is registered with ISRCTN 49474281. FINDINGS: Between June 26, 2013, and Oct 9, 2017, we assessed 3505 patients, of whom 1605 aged up to 91 years were randomly assigned to receive either a standard shunt (n=536), an antibiotic-impregnated shunt (n=538), or a silver shunt (n=531). 1594 had a shunt inserted without evidence of infection at the time of insertion (533 in the standard shunt group, 535 in the antibiotic shunt group, and 526 in the silver shunt group) and were followed up for a median of 22 months (IQR 10-24; 53 withdrew from follow-up). 32 (6%) of 533 evaluable patients in the standard shunt group had a shunt revision for infection, compared with 12 (2%) of 535 evaluable patients in the antibiotic shunt group (cause-specific hazard ratio [csHR] 0·38, 97·5% CI 0·18-0·80, p=0·0038) and 31 (6%) of 526 patients in the silver shunt group (0·99, 0·56-1·74, p=0·96). 135 (25%) patients in the standard shunt group, 127 (23%) in the antibiotic shunt group, and 134 (36%) in the silver shunt group had adverse events, which were not life-threatening and were mostly related to valve or catheter function. INTERPRETATION: The BASICS trial provides evidence to support the adoption of antibiotic shunts in UK patients who are having their first ventriculoperitoneal shunt insertion. This practice will benefit patients of all ages by reducing the risk and harm of shunt infection. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. Lancet. 2019. PMID: 31522843. doi:10.1016/S0140-6736(19)31603-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。